Navigating the Insulin Glargine Market: Key Success Factors for 2023 and Beyond
Navigating the Insulin Glargine Market: Key Success Factors for 2023 and Beyond
According to a research report published by Spherical Insights & Consulting, The Global Insulin Glargine Market Size is Expected to Grow from USD 1.38 Billion in 2023 to USD 2.50 Billion by 2033, at a CAGR of 6.12% during the forecast period 2023-2033.
Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/4502
Insulin glargine, a synthetic version of human insulin, has been approved by the FDA to help adults with type 1 diabetes and children with type 2 diabetes maintain and improve their glycemic control. Long-acting basal insulin, insulin glargine, is administered daily to diabetic patients to regulate their blood sugar levels. It helps diabetics eliminate blood sugar. It is a naturally occurring synthetic form of insulin. Additionally, it is used to limit the amount of sugar that the liver can produce. Since it has an effect that lasts longer than 24 hours, it can be taken once daily. Insulin glargine’s global market is anticipated to grow steadily throughout the forecast period due to the rising number of diabetics. Furthermore, the prevalence of type 1 and type 2 diabetes rises, there is an increased need for insulin glargine treatments, which effectively regulate blood sugar levels. Improvements in glycemic control in insulin formulations, particularly the long-acting basal insulin analog glargine, have led to the market’s expansion. Doctors and patients preferring insulin analogs over traditional insulins because of their predictable absorption and decreased risk of hypoglycemia has also led to an increase in the demand for glycerine. However, market entry is delayed by the availability of biosimilars and substitute insulin products, competition from generic substitutes following patent expiration, and stringent regulatory processes.
Buy Now Full Report: https://www.sphericalinsights.com/checkout/4502
Browse key industry insights spread across 230 pages with 110 Market data tables and figures & charts from the report on The Global Insulin Glargine Market Size, Share, and COVID-19 Impact Analysis, By Type (Lantus, Basaglar, Toujeo, Soliqua, Rezvoglar, and Others), By Diabetes Type (Type 2 Diabetes, Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033
The lantus segment is expected to hold the greatest market share through the forecast period.
On the basis of the type, the global insulin glargine market is divided into lantus, basaglar, toujeo, soliqua, rezvoglar, and others. Among these, the lantus segment is expected to hold the greatest market share through the forecast period. This is attributed to the Lantus has become a well-known brand among doctors and patients. For many diabetic patients, it is the recommended course of therapy because it can control blood sugar levels throughout the day with a single dose. When compared to vials, the availability of Lantus in prefilled pen devices has significantly improved adherence and usability.
The type 2 diabetes segment is expected to hold the greatest market share through the forecast period.
On the basis of the diabetes type, the global insulin glargine market is categorized into type 2 diabetes, type 1 diabetes. Among these, the type 2 diabetes segment is expected to hold the greatest market share through the forecast period. This is attributed to the long-acting nature and ability to effectively control blood sugar levels over an extended period, insulin glargine is frequently given for the management of type 2 diabetes. Early lifestyle changes and oral medications can help people with type 2 diabetes control their illness.
The retail pharmacies segment is expected to hold the greatest revenue share during the projection period.
On the basis of the distribution channel, the global insulin glargine market is divided into hospital pharmacies, online pharmacies, and retail pharmacies. Among these, the retail pharmacies segment is expected to hold the greatest revenue share during the projection period. This is attributed to the retail pharmacies are increasingly becoming the preferred choice for type 2 diabetes patients due to convenience. Local pharmacies make it easier for busy individuals to pick up medications and insulin supplies during their weekly trips. Compared to going to hospitals or specialty pharmacies.
Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/4502
North America is expected to hold the greatest share of the global insulin glargine market over the predicted timeframe.
North America is expected to hold the greatest share of the global insulin glargine market over the predicted timeframe. The vast diabetic population in the United States contributes significantly to its leadership position. With approximately one in ten Americans suffering from diabetes, there is a high need for long-acting insulin treatments such as insulin glargine insulin medications like Lantus and Basaglar have been actively promoted by the top insulin manufacturers, including Sanofi, Eli Lilly, and Novo Nordisk, through marketing campaigns aimed at doctors and patients.
Asia Pacific is anticipated to grow at a rapid CAGR growth of the global insulin glargine market during the forecast period. Several socioeconomic factors are responsible for this increase. The Asia Pacific region’s growing diabetes prevalence is a result of several factors, including rapid urbanization, rising economic levels, and an aging population. Increased access to and coverage of healthcare also makes it possible for more diabetics to select patented medications like insulin glargine. Asian patients can now more easily receive glargine medication due to their affordable costs.
Major vendors in the global insulin glargine market are Biocon, Gan & Lee, Sanofi, Kalbe Pharma, Nova Nordisk AS, Cipla Inc., Lupin Ltd, Pfizer Inc., Ypsomed AG, Wockhardt, Elli Lilly, Biogenomics Ltd., Polus Biopharm, and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In April 2023, Rezvoglar (insulin glargine-aglr), the second interchangeable insulin biosimilar to be commercially marketed to diabetic patients in the United States, was introduced to the market by Eli Lilly and Company.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global insulin glargine market based on the below-mentioned segments:
Global Insulin Glargine Market, By Type
- Lantus
- Basaglar
- Toujeo
- Soliqua
- Rezvoglar
- Others
Global Insulin Glargine Market, By Diabetes Type
- Type 2 Diabetes
- Type 1 Diabetes
Global Insulin Glargine Market, By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Global Insulin Glargine Market, By Regional
- North America
-
- US
- Canada
- Mexico
- Europe
-
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
-
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
-
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
-
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
Browse Related Reports:
Global Digoxin Market Size, Share, and COVID-19 Impact Analysis, By Type (Purity Below 98% and Purity Above 98%), By Application (Injection Product and Tablet Product), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
Global Pterostilbene Powder Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Natural Pterostilbene and Synthetic Stilbene), By Applications (Cosmetics, Dietary Supplements, Food and Beverages, and Pharmaceuticals), By Distribution Channel (Specialty Stores, Online Stores, Supermarkets, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
Global Anti-aging Supplements Market Size, Share, and COVID-19 Impact Analysis, By Ingredient (Collagen, Resveratrol, Vitamins, Minerals, Hyaluronic Acid, NMN, Others), By Application (Hair, Skin, and Nail Care, Bone and Joint Health, Energy and Stamina, Others), By Distribution Channel (Offline and Online), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
Global Benidipine Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Capsules, Tablets, and Others), By Indications (Angina Pectoris, Hypertension, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
About Spherical Insights & Consulting
Spherical Insights & Consulting is a leading market research and consulting firm providing actionable insights, quantitative forecasting, and trend analysis to support business decision-making. The firm serves industries such as finance, government, industrial sectors, and corporations, helping them achieve strategic growth.
Contact Us:
📞 US: +1 303 800 4326
📞 APAC: +91 90289 24100
📧 Email: inquiry@sphericalinsights.com | sales@sphericalinsights.com
🌐 Website: Contact Us
